Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia


 

2021 Update on ET in BC: Palbociclib+ET in HR+/HER2- Normal Disease After Neoadjuvant Chemo & Surgery, Abemaciclib in High-Risk Early Stage HR+/HER2- Disease - Are There IDFS Benefits?

132 views
March 5, 2021
Comments 0
Login to view comments. Click here to Login